Baltimore-based Insilico Medicine landed a new strategic investment from Chinese biotech company WuXi AppTec.
The amount of the funding was not disclosed, but the investment also includes a strategic partnership between Insilico and WuXi, which specializes in contract research for the pharmaceutical and medical device industries.
{iframe}https://technical.ly/baltimore/2018/06/13/insilico-medicine-receives-strategic-investment-from-chinese-biotech-firm/?utm_campaign=Baltimore%20Editorial%20Email&utm_source=hs_email&utm_medium=email&utm_content=63734800&_hsenc=p2ANqtz-98-OZdnhEQM1zymqxMVylgpRm7F1mQNOf1acv5Q9SLkA2LkShSWmONpQpRuL3a4DBH8Cfcrk229Srx61qxuyoWjL8tBA&_hsmi=63734800{/iframe}